Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + prilocaine is a topical anesthetic combination, often marketed under the brand name EMLA, consisting of two amide-type local anesthetics. It functions by stabilizing neuronal membranes through the inhibition of voltage-gated sodium channels, thereby preventing the initiation and conduction of nerve impulses. This specific combination is being utilized by University Hospital, Angers, in clinical studies to assess cutaneous microcirculatory vasomotor reserve. By applying the cream as a chemical stimulus, researchers can evaluate the physiological response of the microvasculature, providing a methodology to investigate microvascular dysfunction in conditions such as diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + prilocaine (Centre Hospitalier Universitaire d'Angers).